|
|
Adiponectin: mechanisms and new therapeutic approaches for restoring diabetic heart sensitivity to ischemic post-conditioning |
Tingting Wang1,2(), Shanglong Yao1, Zhengyuan Xia2(), Michael G. Irwin2 |
1. Department of Anesthesiology and Critical Care, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2. Department of Anesthesiology, The University of Hong Kong, Hong Kong SAR, China |
|
|
Abstract Systemic inflammatory response following myocardial ischemia-reperfusion injury (IRI) to a specific organ may cause injuries. Ischemic post-conditioning (IPostC) has emerged as a promising method for myocardial protection against IRI both in experimental and in clinical settings. Enhancement of endogenous nitric oxide (NO) is one of the major mechanisms by which IPostC confers cardioprotection. However, the sensitivity of the diabetic heart to IPostC is impaired and the underlying mechanism is unknown. Adiponectin (APN) is an adipocyte-derived plasma protein with anti-diabetic and anti-inflammatory properties. Plasma levels of APN are decreased in obese subjects and in patients with type 2 diabetes. APN supplementation has been shown to increase NO production and attenuate myocardial IRI in normal (non-diabetic) animals. However, the effect of APN on myocardial injury in diabetic subjects, especially its potential in restoring the sensitivity of the diabetic heart to IPostC has not been investigated. In the current paper, we discussed the possible reasons why the myocardium of diabetic subjects loses sensitivity to IPostC and also highlighted the potential effectiveness and mechanism of APN in restoring IPostC cardioprotection in diabetes. This review proposes to conduct studies that may facilitate the development of novel and optimal therapies to enhance cardioprotection in patients with severe diseases such as diabetes.
|
Keywords
adiponectin
ischemic post-conditioning
ischemia reperfusion injury
diabetes
|
Corresponding Author(s):
Wang Tingting,Email:wangtingting721@yahoo.com; Xia Zhengyuan,Email:zyxia@hku.hk
|
Issue Date: 05 September 2013
|
|
1 |
Roffi M, Eberli FR. Diabetes and acute coronary syndromes. Best Pract Res Clin Endocrinol Metab 2009; 23(3): 305-316 doi: 10.1016/j.beem.2009.01.003 pmid:19520305
|
2 |
Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS ; DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349(8): 733-742 doi: 10.1056/NEJMoa025142 pmid:12930925
|
3 |
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74(5): 1124-1136 doi: 10.1161/01.CIR.74.5.1124 pmid:3769170
|
4 |
Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285(2): H579-H588 pmid:12860564
|
5 |
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380(1-2): 24-30 doi: 10.1016/j.cca.2007.01.026 pmid:17343838
|
6 |
Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003; 3(3): 207-213 doi: 10.1007/s11892-003-0065-2 pmid:12762967
|
7 |
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-1599 doi: 10.1161/01.ATV.20.6.1595 pmid:10845877
|
8 |
Wang T, Qiao S, Lei S, Liu Y, Ng KF, Xu A, Lam KS, Irwin MG, Xia Z. N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS ONE 2011; 6(8): e23967 doi: 10.1371/journal.pone.0023967 pmid:21912612
|
9 |
Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11(10): 1096-1103 doi: 10.1038/nm1295 pmid:16155579
|
10 |
Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115(11): 1408-1416 doi: 10.1161/CIRCULATIONAHA.106.666941 pmid:17339545
|
11 |
Liu X, Chen H, Zhan B, Xing B, Zhou J, Zhu H, Chen Z. Attenuation of reperfusion injury by renal ischemic postconditioning: the role of NO. Biochem Biophys Res Commun 2007; 359(3): 628-634 doi: 10.1016/j.bbrc.2007.05.129 pmid:17548062
|
12 |
Amour J, Brzezinska AK, Weihrauch D, Billstrom AR, Zielonka J, Krolikowski JG, Bienengraeber MW, Warltier DC, Pratt PFJ Jr, Kersten JR. Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology 2009; 110(2): 317-325 pmid:19194158
|
13 |
Lecour S. Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47(1): 32-40 doi: 10.1016/j.yjmcc.2009.03.019 pmid:19344728
|
14 |
Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008; 79(1): 127-133 doi: 10.1093/cvr/cvn067 pmid:18339648
|
15 |
Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291(2): H827-H834 doi: 10.1152/ajpheart.00003.2006 pmid:16517948
|
16 |
Oshima Y, Fujio Y, Nakanishi T, Itoh N, Yamamoto Y, Negoro S, Tanaka K, Kishimoto T, Kawase I, Azuma J. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 2005; 65(2): 428-435 doi: 10.1016/j.cardiores.2004.10.021 pmid:15639482
|
17 |
Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001; 98(16): 9050-9055 doi: 10.1073/pnas.161283798 pmid:11481471
|
18 |
Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 2009; 104(1): 15-18 doi: 10.1161/CIRCRESAHA.108.186429 pmid:19038864
|
19 |
Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102(1): 131-135 doi: 10.1161/CIRCRESAHA.107.164699 pmid:17967780
|
20 |
Yin X, Zheng Y, Zhai X, Zhao X, Cai L.Diabetic inhibition of preconditioning- and postconditioning-mediated myocardial protection against ischemia/reperfusion injury. Exp Diabetes Res 2012 ; 2012: 198048 doi: 10.1155/2012/198048
|
21 |
Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49(2): 241-248 doi: 10.1161/01.HYP.0000254415.31362.a7 pmid:17190878
|
23 |
Nagareddy PR, Xia Z, McNeill JH, MacLeod KM. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol 2005; 289(5): H2144-H2152 doi: 10.1152/ajpheart.00591.2005 pmid:16006542
|
24 |
Xia Z, Nagareddy PR, Guo Z, Zhang W, McNeill JH. Antioxidant N-acetylcysteine restores systemic nitric oxide availability and corrects depressions in arterial blood pressure and heart rate in diabetic rats. Free Radic Res 2006; 40(2): 175-184 doi: 10.1080/10715760500484336 pmid:16390827
|
25 |
Nagareddy PR, Xia Z, MacLeod KM, McNeill JH. N-acetylcysteine prevents nitrosative stress-associated depression of blood pressure and heart rate in streptozotocin diabetic rats. J Cardiovasc Pharmacol 2006; 47(4): 513-520 doi: 10.1097/01.fjc.0000211744.93701.25 pmid:16680064
|
26 |
Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007; 100(7): 1089-1098 doi: 10.1161/01.RES.0000264081.78659.45 pmid:17363700
|
27 |
Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84(2): 201-208 doi: 10.1093/cvr/cvp274 pmid:19666677
|
28 |
Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007; 56(1): 127-136 doi: 10.2337/db06-0907 pmid:17192474
|
29 |
Siasos G, Tousoulis D, Kollia C, Oikonomou E, Siasou Z, Stefanadis C, Papavassiliou AG. Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches. Curr Med Chem 2012; 19(8): 1193-1209 doi: 10.2174/092986712799320583 pmid:22257055
|
30 |
Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360(9326): 57-58 doi: 10.1016/S0140-6736(02)09335-2 pmid:12114044
|
31 |
Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, Wong C, Xu A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007; 56(5): 1387-1394 doi: 10.2337/db06-1580 pmid:17287464
|
32 |
Chang J, Li Y, Huang Y, Lam KS, Hoo RL, Wong WT, Cheng KK, Wang Y, Vanhoutte PM, Xu A. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes 2010; 59(11): 2949-2959 doi: 10.2337/db10-0582 pmid:20802255
|
33 |
Cai XJ, Chen L, Li L, Feng M, Li X, Zhang K, Rong YY, Hu XB, Zhang MX, Zhang Y, Zhang M. Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol Endocrinol 2010; 24(1): 218-228 doi: 10.1210/me.2009-0128 pmid:19889816
|
34 |
Liao W, Yu C, Wen J, Jia W, Li G, Ke Y, Zhao S, Campell W. Adiponectin induces interleukin-6 production and activates STAT3 in adult mouse cardiac fibroblasts. Biol Cell 2009; 101(5): 263-272 doi: 10.1042/BC20080117 pmid:18795895
|
35 |
Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003; 278(34): 31629-31639 doi: 10.1074/jbc.M212831200 pmid:12791703
|
36 |
Shin MJ, Lee YP, Kim DW, An JJ, Jang SH, Cho SM, Sheen SH, Lee HR, Kweon HY, Kang SW, Lee KG, Park J, Eum WS, Cho YJ, Choi SY. Transduced PEP-1-AMPK inhibits the LPS-induced expression of COX-2 and iNOS in Raw264.7 cells. BMB Rep 2010; 43(1): 40-45 doi: 10.5483/BMBRep.2010.43.1.040 pmid:20132734
|
37 |
Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 2004; 279(20): 20767-20774 doi: 10.1074/jbc.M401390200 pmid:14985344
|
38 |
Hwang JT, Kwon DY, Park OJ, Kim MS. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2008; 2(4): 323-326 doi: 10.1007/s12263-007-0069-7 pmid:18850225
|
39 |
Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 2008; 295(4): H1580-H1586 doi: 10.1152/ajpheart.00379.2008 pmid:18689499
|
40 |
Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, Murohara T, Walsh K. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 2010; 49(2): 210-220 doi: 10.1016/j.yjmcc.2010.02.021 pmid:20206634
|
41 |
Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292(4): H1655-H1663 doi: 10.1152/ajpheart.01072.2006 pmid:17142348
|
42 |
Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 2007; 292(4): H1728-H1736 doi: 10.1152/ajpheart.01328.2005 pmid:17122189
|
43 |
Peng T, Lu X, Lei M, Feng Q. Endothelial nitric-oxide synthase enhances lipopolysaccharide-stimulated tumor necrosis factor-alpha expression via cAMP-mediated p38 MAPK pathway in cardiomyocytes. J Biol Chem 2003; 278(10): 8099-8105 doi: 10.1074/jbc.M207288200 pmid:12506117
|
44 |
Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118(19): 1915-1919 doi: 10.1161/CIRCULATIONAHA.108.805242 pmid:18981312
|
45 |
Thielmann M, D?rge H, Martin C, Belosjorow S, Schwanke U, van De Sand A, Konietzka I, Büchert A, Krüger A, Schulz R, Heusch G. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002; 90(7): 807-813 doi: 10.1161/01.RES.0000014451.75415.36 pmid:11964374
|
46 |
L’Abbate A, Neglia D, Vecoli C, Novelli M, Ottaviano V, Baldi S, Barsacchi R, Paolicchi A, Masiello P, Drummond GS, McClung JA, Abraham NG. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. Am J Physiol Heart Circ Physiol 2007; 293(6): H3532-H3541 doi: 10.1152/ajpheart.00826.2007 pmid:17906103
|
47 |
Xia Z, Vanhoutte PM. Nitric oxide and protection against cardiac ischemia. Curr Pharm Des 2011; 17(18): 1774-1782 doi: 10.2174/138161211796391047 pmid:21631419
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|